1 / 23

NEW CHALLENGES IN KIDNEY CANCER BEVACIZUMAB

vern
Download Presentation

NEW CHALLENGES IN KIDNEY CANCER BEVACIZUMAB

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

    1. NEW CHALLENGES IN KIDNEY CANCER BEVACIZUMAB Pr Alain Ravaud. Medical Oncology. University Hospital- Bordeaux- France

    2. BEVACIZUMAB Humanized VEGF mAb 93% human Dose : 3mg/kg : Pk similar to optimally effective dose in preclinical mouse model 10 mg/kg max.dose in phase I with no MTD

    4. BEVACIZUMAB. > 1st LINE

    6. BEVACIZUMAB

    7. BEVACIZUMAB 1st targeted drug validating a modification of the natural history of MRCC Validation of angiogenesis as a major event in MRCC natural history as least by the VEGF pathway Manageable safety profile ? go to 1st line ? Explore combination for VEGF or other pathway

    8. BEVACIZUMAB. 1ST LINE

    9. BEVACIZUMAB. 1ST LINE

    10. BEVACIZUMAB. 1ST LINE

    11. BEVACIZUMAB. 1ST LINE

    13. AVOREN A randomized, double-blind, placebo-controlled phase III study to evaluate the efficacy and safety of bevacizumab in combination with interferon alfa-2a versus interferon alfa-2a and placebo as first-line treatment administered to patients with MRCC

    18. PFS AND MOTZER’S RISK GROUP

    22. BEVACIZUMAB + OTHERS Bevacizumab + anti VEGF pathway + Sunitinib : phase I ? II + Sorafenib : phase I ? II Bevacizumab + mTOR inhition + CCI : phase I + RAD 001 : phase I

    23. BEVACIZUMAB Highly effective in MRCC Effective as 1st line or following immunotherapy Low level of complete response Unknown : Bevacizumab + INF or Bevacizumab alone ? New option in 1st line in MRCC with Sunitinib as the standard

More Related